Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection

Antiviral Research

Volumn 92, Issue 2, 2011, Pages 313-318

  Hakki, Morgan ^a   Drummond, Coyne ^a   Houser, Benjamin ^a   Marousek, Gail ^b   Chou, Sunwen ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Antiviral; Cytomegalovirus; Drug resistance; Maribavir; Nucleolus; UL27

Indexed keywords

BENZIMIDAVIR; PUL97 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ALLELIC EXCLUSION; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL NUCLEUS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA POLYMORPHISM; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; NUCLEOLAR LOCALIZATION SIGNAL; PHENOTYPE; PLASMID; PRIORITY JOURNAL; TRANSIENT TRANSFECTION; VIRUS STRAIN;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELL NUCLEUS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOPLASM; DRUG RESISTANCE, VIRAL; HUMANS; MUTATION, MISSENSE; RIBONUCLEOSIDES; VIRAL PROTEINS; VIRUS REPLICATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; MUSHROOM BACILLIFORM VIRUS;

EID: 80054848456     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.08.019     Document Type: Article

References (33)

1. Ahn J.H., Jang W.J., Hayward G.S. The human cytomegalovirus IE2 and UL112-113 proteins accumulate in viral DNA replication compartments that initiate from the periphery of promyelocytic leukemia protein-associated nuclear bodies (PODs or ND10). J. Virol. 1999, 73(12):10458-10471.
2. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith A.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., Koszalka G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 2002, 46(8):2365-2372.
3. Boeckh M., Geballe A.P. Cytomegalovirus: pathogen, paradigm, and puzzle. J. Clin. Invest. 2011, 121(5):1673-1689.
4. Boisvert F.M., van Koningsbruggen S., Navascues J., Lamond A.I. The multifunctional nucleolus. Nat. Rev. Mol. Cell. Biol. 2007, 8(7):574-585.
5. Boyne J.R., Whitehouse A. Nucleolar trafficking is essential for nuclear export of intronless herpesvirus mRNA. Proc. Natl. Acad. Sci. USA 2006, 103(41):15190-15195.
6. Boyne J.R., Whitehouse A. Nucleolar disruption impairs Kaposi's sarcoma-associated herpesvirus ORF57-mediated nuclear export of intronless viral mRNAs. FEBS Lett. 2009, 583(22):3549-3556.
7. Carmo-Fonseca M., Mendes-Soares L., Campos I. To be or not to be in the nucleolus. Nat. Cell Biol. 2000, 2(6):E107-E112.
8. Catez F., Erard M., Schaerer-Uthurralt N., Kindbeiter K., Madjar J.J., Diaz J.J. Unique motif for nucleolar retention and nuclear export regulated by phosphorylation. Mol. Cell Biol. 2002, 22(4):1126-1139.
9. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 2008, 18:233-246.
10. Chou S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob. Agents Chemother. 2009, 53(1):81-85.
11. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob. Agents Chemother. 2010, 54(6):2371-2378.
12. Chou S., Marousek G.I., Senters A.E., Davis M.G., Biron K.K. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 2004, 78(13):7124-7130.
13. Chou S., Van Wechel L.C., Lichy H.M., Marousek G.I. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 2005, 49(7):2710-2715.
14. Chou S., Van Wechel L.C., Marousek G.I. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrob. Agents Chemother. 2006, 50(7):2557-2559.
15. Chou S., Van Wechel L.C., Marousek G.I. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis. 2007, 196(1):91-94.
16. Cochrane A.W., Perkins A., Rosen C.A. Identification of sequences important in the nucleolar localization of human immunodeficiency virus Rev: relevance of nucleolar localization to function. J. Virol. 1990, 64(2):881-885.
17. Emmott E., Hiscox J.A. Nucleolar targeting: the hub of the matter. EMBO Rep. 2009, 10(3):231-238.
18. Fazakerley J.K., Boyd A., Mikkola M.L., Kaariainen L. A single amino acid change in the nuclear localization sequence of the nsP2 protein affects the neurovirulence of Semliki Forest virus. J. Virol. 2002, 76(1):392-396.
19. Greco A. Involvement of the nucleolus in replication of human viruses. Rev. Med. Virol. 2009, 19(4):201-214.
20. Komazin G., Ptak R.G., Emmer B.T., Townsend L.B., Drach J.C. Resistance of human cytomegalovirus to the benzimidazole l-ribonucleoside maribavir maps to UL27. J. Virol. 2003, 77(21):11499-11506.
21. Korgaonkar C., Hagen J., Tompkins V., Frazier A.A., Allamargot C., Quelle F.W., Quelle D.E. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol. Cell Biol. 2005, 25(4):1258-1271.
22. Lurain N.S., Chou S. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 2010, 23(4):689-712.
23. Mekhail K., Gunaratnam L., Bonicalzi M.E., Lee S. HIF activation by pH-dependent nucleolar sequestration of VHL. Nat. Cell Biol. 2004, 6(7):642-647.
24. Meng L., Yasumoto H., Tsai R.Y. Multiple controls regulate nucleostemin partitioning between nucleolus and nucleoplasm. J. Cell Sci. 2006, 119(Pt 24):5124-5136.
25. Michienzi A., Li S., Zaia J.A., Rossi J.J. A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc. Natl. Acad. Sci. USA 2002, 99(22):14047-14052.
26. Niedick I., Froese N., Oumard A., Mueller P.P., Nourbakhsh M., Hauser H., Koster M. Nucleolar localization and mobility analysis of the NF-kappaB repressing factor NRF. J. Cell Sci. 2004, 117(Pt 16):3447-3458.
27. Pederson T., Tsai R.Y. In search of nonribosomal nucleolar protein function and regulation. J. Cell Biol. 2009, 184(6):771-776.
28. Prichard M.N., Kern E.R. The search for new therapies for human cytomegalovirus infections. Virus Res. 2011, 157(2):212-221.
29. Prichard M.N., Quenelle D.C., Bidanset D.J., Komazin G., Chou S., Drach J.C., Kern E.R. Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice. Virol. J. 2006, 3:18.
30. Reitsma J.M., Savaryn J.P., Faust K., Sato H., Halligan B.D., Terhune S.S. Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest. Cell Host Microbe 2011, 9(2):103-114.
31. Tischer B.K., Smith G.A., Osterrieder N. En passant mutagenesis: a two step markerless red recombination system. Methods Mol. Biol. 2010, 634:421-430.
32. Tsai R.Y., McKay R.D. A multistep, GTP-driven mechanism controlling the dynamic cycling of nucleostemin. J. Cell Biol. 2005, 168(2):179-184.
33. Zhang Y., Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009, 16(5):369-377.